Comfora
trial impact
Click here to Register

Elmiron or Comfora:

              Who out there is not worried about their money? Elmiron is burning a big-hole in the pockets of the patients. When you have a chronic illness like IC, money cannot be.

               Comfora is orally bioavailable Pentosan Polysulfate Sodium. Its mechanism of action is thought to be adherence to the bladder surface supplementing the defective natural glycosaminoglycan layer. It is hypothesized that this action ameliorates the symptoms of interstitial cystitis. Orally administered pentosan has a urinary excretion half-life of 4.4 hours for the unchanged drug. A single dose is completely eliminated in 144 hours.

               The recommended dose is 300 mg/day taken as one 100 mg capsule orally 3 times daily. The capsules should be taken with water at least 1 hour before meals or 2 hours after meals

              Some patients with interstitial cystitis may require 6 to 8 weeks of therapy with pentosan to achieve relief of symptoms. Long-term continuation of pentosan therapy is necessary for persistent therapeutic effect.

              Elmiron and Comfora only differ in their price tag. Elmiron placed at a higher value is not affordable by all. Swati Spentose Pvt. Ltd. took the initiative in launching the only Indian Brand- Comfora. large segment of patients, for whom it was difficult to afford Elmiron can now buy it and lead a comforting life even during IC.

             The next issue will cover the All-India USICONS held at the capital as well as the regional USICONS attended by our expert staff.

             The symptoms in women exacerbate just before or during menstruation, during ovulation or if they are taking contraceptive pills. It should be emphasized, however, that many patients never progress further than a relatively mild form of IC.

Newsletters

References
  1. Panzera AK. Interstitial cystitis/Painful bladder syndrome. Urol Nurs. 2007;27(1):13-19.
  2. Carr LK, Corocs J, Njckel C, Teichman J. Diagnosis of Intersitial cystitis June 2007. Can Urol Assoc J. 2009;3(1):81-86.
  3. Van de Merve JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclaturefor painful bladder syndrome/interstitial cystitis: An ESSIC proposal. European Urology. 2008;53(1):60-67.
  4. Hanno PM. Interstitial cystitis - Epidemiology, Diagnostic criteria, Clinical Markers. Rev Urol. 2002;4(1):S3-S8.
  5. Heck BN. Interstitial cystitis:Enhancing early identification in primary care settings. JNP. 2007;3(8):509-519.
  6. Mattox TF. Interstitial cystitis in adolscents and children:a review. J Pediatr Adolesc Gynecol. 2004;17:7-11.
  7. Teichman JMH, Parsons CL. Contemporary clincal presentation of interstitial cystitis. Urology. 2007;69(4A):41-47.
  8. Association of Reproductive Health Professionals. Screening, treatment, and management of IC/PBS. www arhp org. Accessed March 9, 2009.
  9. Evans RJ. Pathophysiology and clinical presentation of interstitial cystitis. Avd Stud Pharm. 2005;8-14.
  10. National Kidney and Urologic diseases Information Clearinghouse(NKUDIC). Interstitial cystitis/ painful bladder syndrome. www kidney niddk nih gov. Accessed March 9, 2009.